Connect Biopharma announced the appointment of industry veteran Jim Schoeneck as a director, expanding the size of its Board of Directors from six to seven directors, effective July 22, 2025. This appointment aims to strengthen the company's strategic leadership.
Mr. Schoeneck brings over 40 years of experience in drug development and commercialization, having guided companies through significant transformation and growth. He currently serves as Chairman of the Board of Directors for FibroGen, Inc. and Calidi Biotherapeutics, Inc.
CEO Barry Quart stated that the company looks forward to leveraging Mr. Schoeneck’s strategic and commercial acumen as it advances its Phase 2 Seabreeze STAT studies towards clinical data expected in the first half of 2026. His expertise is expected to be invaluable for the company's long-term commercial success.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.